Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis.
H epatitis C virus (HCV)-mediated liver diseases are major health issues, with an estimated 300 million people worldwide and 4 million in the United States affected (1) . Most often, HCV infection leads to gradual development of fibrosis and cirrhosis-end-stage liver diseases-and poses significant risk for developing hepatocellular carcinoma (HCC) (2) . CCL2, or monocyte chemotactic protein 1, is a cytokine (11 kDa) of the CC chemokine family secreted by a variety of cell types, including fibroblasts; peripheral blood mononuclear cells; monocytes; macrophages; and epithelial, endothelial, smooth muscle, and dendritic and microglial cells (3) (4) (5) (6) . CCL2 is upregulated in patients with chronic liver diseases, such as alcoholic hepatitis, nonalcoholic steatohepatitis (NASH), and HCV infection, which are accompanied by inflammation (7) (8) (9) . In mice, removal of the cytokine interleukin-6 (IL-6) and components of the IL-6 receptor (IL-6R) complex and STAT3 impairs CCL2 expression (10) . IL-6 transmits a signal through components of the IL-6R complex, through dimerization of the ligand binding IL-6R and non-ligand binding gp130 (11) . Upon ligand binding, JAK1, JAK2, and TYK2 are activated by phosphorylation, which in turn phosphorylates gp130 (12) . Phosphorylated gp130 provides a docking site for the DNA binding STAT1 and STAT3 (12) . The STATs, including STAT3, are then phosphorylated by activated JAKs in the receptor complex, leading to dimerization, followed by nuclear translocation and activation of target genes (12, 13) . The DNA binding transcription factor proviral integration oncogene (SPI1/PU.1) regulates gene expression during hematopoietic differentiation and development, and its knockdown results in the absence of B-lymphoid and myeloid lineage cells (14) . PU.1 is required for the development and maintenance of lymphoid and myeloid lineages of fetal liver hematopoietic stem cells (15) . The homodimeric DNA binding bZIP transcription factor CCAAT/ CEBP␣ controls cell proliferation and differentiation (16) . In a subset of patients diagnosed with HCC, CEBP␣ is upregulated and controls the expression of genes, including hepatocyte-specific microRNA-122 (miRNA-122), involved in hepatocarcinogenesis (17, 18) .
In recent years, miRNAs have been shown to play an important role in immune evasion, allograft rejection, cell cycle regulation, and cancer progression (19) (20) (21) . HCV infection has been shown to result in aberrant miRNA expression that regulates HCV particle entry, propagation, and gene expression mechanisms, thus playing a pivotal role in host immune evasion and inflammatory responses (22, 23) . In this report, we demonstrate that HCV-mediated regulation of miRNA-449a and miRNA-107 results in upregulation of CCL2 and modulates components of the IL-6R complex, which we propose will result in HCV-mediated induction of inflammatory responses and fibrosis.
MATERIALS AND METHODS
Patients. Liver biopsy specimens were obtained from 10 healthy-donor livers (control), 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 chronic-HCV patients (see Table S1 in the supplemental material). Patients with HIV and/or hepatitis B virus infection were not included in this study. The collection of human samples and the studies were approved by the Human Research Protection Committee at Washington University (protocol 201104075), and the patients were enrolled after obtaining written informed consent.
Plasmids and siRNA constructs. For the reporter constructs, the CCL2 promoter regions were amplified from human genomic DNA (Zyagen, CA) by PCR using iProof High-Fidelity DNA Polymerase (Bio-Rad, CA). The PCR products were subcloned into the pGL4.11 vector (Promega, WI) upstream of a luciferase gene using the KpnI/EcoRV restriction sites. Mutation in the STAT3 binding site in the base pair (bp) Ϫ300 reporter construct was carried out using PCR. pCMV-XL4-PU.1 (SC315715) and pCMV-XL4-STAT3 (SC124165), Hsa-miRNA-449a (SC400399), Hsa-miRNA-107 (SC400023), and controls were obtained from Origene, MD. The construction of pcDNA-CEBP␣ is described elsewhere (23) . Small interfering RNAs (siRNAs) specific for PU.1 (sc-36330), STAT3 (sc-29493), CEBP␣ (sc-37047), IL-6R (sc-35663), JAK1 (sc-35719), and a control (sc-37007) were purchased from Santa Cruz Biotechnology, CA. 3=-untranslated-region (UTR) clones of IL-6R (HmiT009673-MT01) and JAK1 (HmiT009849-MT01) were purchased from Genecopoeia, MD. Computational analysis to identify promoterbound transcription factors was done using the Transcription Element Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess). miRNA target gene analysis was done using the website http://www .targetscan.org. miRNA and mRNA expression analysis. Total RNA was isolated from the human hepatocytes or liver biopsy specimens using the RNA aqueous kit (Ambion, NY). miRNA-449a and miRNA-107 levels were determined using TaqMan miRNA assays and TaqMan Universal Master Mix-II (Life Technologies, NY) with predesigned primers. Quantitative PCR (qPCR) to analyze CCL2, PU.1, STAT3, CEBP␣, JAK1, and IL-6R was performed as described previously (23) . Each TaqMan assay was run in triplicate. The ⌬⌬C T values were calculated by normalizing the threshold cycle (C T ) values with GAPDH (glyceraldehyde-3-phosphate dehydrogenase gene) or RNU6B expression and the respective gene expression in control samples.
Primary hepatocytes and HEPG2 cell line transfection. Primary human hepatocytes (Life Technologies) and HEPG2 (ATCC) cells were grown and gene/siRNA transfections were carried out as described previously (23) . The cytokine IL-6 (50 ng/ml; Sigma, MO) was added for 6 h wherever indicated. The optimal amount of IL-6 required for induction was determined by dose-dependent analyses. The knockdown efficiency was measured by qPCR.
Immunofluorescence microscopy and Western blotting. For localization of PU.1, STAT3, and CEBP␣, 50,000 HEPG2 cells were grown on coverslips in 24-well plates. Immunostaining was done as described previously (23) . The antibodies (Abs) used for Western blotting and immunofluorescence were goat anti-CCL2 (sc-1304), mouse anti-JAK1 (sc-376996), rabbit anti-IL-6R (sc-661), mouse anti-pSTAT3 (sc-8059), goat anti-CEBP␣ (sc-9315), and rabbit anti-PU.1 (sc-352). Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (sc-358916), rhodamine-conjugated rabbit anti-goat IgG (sc-3945), FITC-conjugated goat anti-rabbit IgG (sc-2012), rhodamine-conjugated goat anti-mouse IgG (sc-2092), FITC-conjugated mouse anti-rabbit IgG (sc-2359), and rhodamine-conjugated mouse anti-goat IgG (sc-2490) were used as secondary reagents to demonstrate specific binding. The images were captured using an Eclipse 80i fluorescence microscope (Nikon, NY) and processed using Metamorph version 6.3r2 software (Molecular Devices, CA).
Luciferase reporter assay. Hepatocytes (1 ϫ 10 5 ) were transfected in 24-well plates as described previously (23) with 1 g pGL4.11 luciferase reporter vector driven by the CCL2 promoters, along with 2 g control vector or vector expressing miRNA-449a, miRNA-107, PU.1, STAT3, or CEBP␣ or 80 pmol of either control siRNA or siRNA specific for IL-6R, JAK1, PU.1, STAT3, or CEBP␣. To control for efficiency of transfection, 0.1 g of pRL-TK (Promega, WI), which expresses Renilla luciferase, was included. For miRNA target analysis, hepatocytes were transfected with 2 g of a luciferase reporter construct containing IL-6R 3= UTR or JAK1 3= UTR, along with either control vector or vector expressing miRNA-449a or miRNA-107. Luciferase activity was measured 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega, WI), and the results were normalized to Renilla luciferase.
Coimmunoprecipitation. For immunoprecipitation of PU.1 with CEBP␣, of PU.1 with pSTAT3, or of pSTAT3 with CEBP␣, IL-6-treated hepatocytes (1 ϫ 10 6 ) were used as described by Sarma and Yaseen (24) . One microgram of normal goat IgG, normal mouse IgG, goat anti-CEBP␣, or mouse anti-pSTAT3 was used to immunoprecipitate the protein complexes. PU.1 or pSTAT3 was detected with rabbit anti-PU.1 or mouse anti-pSTAT3, respectively.
ChIP. Chromatin immunoprecipitation (ChIP) was carried out with ChIP-IT Express (Active Motif, CA) according to the manufacturer's instructions, as described previously (23) . One microgram of Abs for control IgG, PU.1, pSTAT3, or CEBP␣ was used to immunoprecipitate DNAprotein complexes. CCL2 promoter regions were amplified using PCR and resolved on 2% agarose gels. The images were acquired with the Chemidoc XRS System (Bio-Rad).
RESULTS
Specific downregulation of miRNA-107 and miRNA-449a and upregulation of CCL2 in HCV livers with fibrosis. We previously reported differential modulation of miRNAs, including miRNA-107 and miRNA-449a, in HCV patients (23, 25) . To determine the expression levels of miRNA-107 and miRNA-449a following HCV infection, biopsy specimens were collected from 10 normal livers from cadaveric donors, 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 chronic-HCV patients. Expression analysis using qPCR demonstrated that miRNA-107 is specifically downregulated by more than 2-fold (2.2-fold) in HCV-infected patients (Fig. 1A) . In contrast, no significant difference in the expression of miRNA-107 was observed in alcoholic-hepatitis, NASH, and normal livers. Similarly, expression of miRNA-449a was also found to be specifically downregulated more than 2-fold (2.8-fold) only in the HCV-infected livers, but not in other disease conditions ( Fig.  1B) . RNU6B was used as the internal control.
Expression analysis showed upregulation of CCL2 in alcoholic hepatitis (6.2-fold), NASH (5.8-fold), and HCV (10.0-fold) compared to normal livers (Fig. 1C ). Expression of CCL2 in HCV livers was significantly higher than in those of patients with alcoholic hepatitis and NASH (P Ͻ 0.001).
IL-6 regulates CCL2 activation through the IL-6R complex. Components of the IL-6R complex were shown to be essential for CCL2 expression (10) . To determine the role of IL-6 in CCL2 expression, the reporter construct containing the Ϫ2,000-bp re-gion of the human CCL2 promoter was transfected into human hepatocytes and treated or not with IL-6, and luciferase activity was measured. More than a 4-fold (4.7-fold) increase in the CCL2 reporter activity was observed in IL-6-treated cells compared to the untreated cells, which was further confirmed by immunoblotting ( Fig. 2A ). This strongly suggests that IL-6 activates CCL2 through modulation of upstream transcription factors. Further, knockdown of the IL-6 cell surface receptor gene, IL-6R, resulted in a 2-fold decrease in IL-6-mediated CCL2 activation and protein expression compared to controls ( Fig. 2A ). Knockdown of JAK1 also resulted in significant impairment (1.8-fold) of IL-6-mediated CCL2 reporter activity and protein expression ( Fig. 2B ). Quantitative gene expression analysis showed 88% and 86% knockdown of IL-6R and JAK1, respectively, in siRNA-treated cells (see Fig. S1 in the supplemental material).
Identification of putative DNA binding transcription factors in the CCL2 promoter regions. To identify DNA binding transcription factors that regulate the expression of CCL2, a computational analysis of Ϫ2,000 bp of the promoter region was performed using TESS. This bioinformatics analysis identified two putative DNA binding sites for CEBP␣ (GCAAT), four sites for PU.1 (GAGGAA), and one site for STAT3 (TTCCTG GAA) at the bp Ϫ138 position (Fig. 3A) in close proximity to each other, suggesting that these three transcription factors may be part of a transcriptional-regulatory complex that mediates CCL2 expression.
To demonstrate that these transcription factors regulate CCL2 expression, human hepatocytes were transfected with the CCL2 reporter construct, along with either empty vector or vector expressing PU.1, STAT3, or CEBP␣, and treated with IL-6 ( Fig. 3B) . A significant increase in reporter activity was observed compared to the empty vector with overexpression of PU.1 (3.3-fold), STAT3 (7.0-fold), and CEBP␣ (5.4-fold) ( Fig. 3B ). To determine whether these transcription factors cooperate in activating CCL2, two of the transcription factors (PU.1/STAT3, PU.1/CEBP␣, or STAT3/ CEBP␣) were cotransfected into hepatocytes, along with the CCL2 reporter construct. Cotransfection resulted in a significant increase in reporter activity compared to either factor alone, suggesting cooperation between the factors in regulating CCL2 expression ( Fig. 3B , top). Overexpression of the transcription factors in the hepatocytes was confirmed by immunoblotting ( Fig. 3B ).
To further demonstrate that these transcription factors are required for IL-6-mediated expression of CCL2, human hepatocytes were transfected with the CCL2 reporter construct, along with either control siRNAs or siRNAs specific for PU.1, STAT3, or CEBP␣, and treated with IL-6. Knockdown of PU.1 resulted in 28%, that of STAT3 resulted in 37%, and that of CEBP␣ resulted in 25% decrease in the CCL2 reporter activity compared to the control (Fig. 3C ). Knockdown of any two transcription factors (PU.1/STAT3, PU.1/CEBP␣, or STAT3/CEBP␣) resulted in a significant decrease in reporter activity compared to knockdown of either factor alone, suggesting cooperation between these factors in the transcriptional activation of CCL2 (Fig.  3C ). Quantitative gene expression analysis showed 77%, 73%, and 75% knockdown of PU.1, STAT3, and CEBP␣ in siRNAtreated cells (see Fig. S1 in the supplemental material). However, coexpression or coknockdown of PU.1, STAT3, and CEBP␣ together impaired cell viability.
To determine whether the transcription factor binding sites are essential, deletion mutants were designed based on the locations of the DNA binding sites for CEBP␣, PU.1, and STAT3 on the CCL2 promoter. These deletion mutants ( Fig. 3D , black bars) were introduced into hepatocytes, treated or not with IL-6, and the luciferase activity was measured. Sequential deletion of the CCL2 promoter impaired IL-6-mediated transcriptional induction compared to the bp Ϫ2000 promoter (Fig. 3D ). No signifi- cant differences in reporter activity were observed in untreated cells, indicating that IL-6 is required for transcriptional regulators to activate CCL2 (Fig. 3D ). For reporter constructs (bp Ϫ2000, Ϫ800, and Ϫ300), IL-6 treatment resulted in more than 2.5-fold increase in reporter activity compared to untreated constructs. However, a point mutation in the STAT3 binding site on the CCL2 promoter completely abolished the IL-6 response (Fig. 3D ). This indicates that STAT3, along with CEBP␣ and PU.1, plays a major role in IL-6-mediated CCL2 induction.
CEBP␣, PU.1, and STAT3 form a transcriptional-activation complex and bind to the CCL2 promoter. To determine whether CEBP␣, PU.1, and STAT3 bind to adjacent DNA binding sites on the CCL2 promoter, DNA-protein complexes from IL-6-treated hepatocytes were immunoprecipitated with anti-CEBP␣,r anti-PU.1, anti-STAT3, or control IgGs. ChIP and PCR using primers specific for CCL2 promoter regions (Fig. 4A , black bars) demonstrated that CEBP␣, PU.1, and STAT3 bind to the promoter (Fig.  4B ). CEBP␣ binds strongly to the Ϫ800/Ϫ1200 and Ϫ400/Ϫ800 regions and weakly to the Ϫ1/Ϫ400 region; PU.1 binds strongly to the Ϫ800/Ϫ1200 and Ϫ1/Ϫ400 regions and weakly to the Ϫ400/ Ϫ800 region of the CCL2 promoter. The observed binding of CEBP␣ in the Ϫ800/Ϫ1200 region is likely due to the presence of binding sites within Ϯ250 bp of the PCR amplicon. The DNA binding pattern of CEBP␣ and PU.1 strongly correlates with the locations of the consensus binding sites on the CCL2 promoter. STAT3 binds strongly to the Ϫ1/Ϫ400 region, encompassing the binding site (bp Ϫ138). ChIP with the control IgGs did not enrich CCL2 promoter regions, demonstrating the specificity for these transcription factors. No binding was observed in PCRs carried out with primers specific for the Ϫ300/Ϫ700 region of the ACTIN (ACTA1) promoter that lacks these binding sites (Fig. 4B) .
To demonstrate that these transcription factors are interdependent, human hepatocytes were transfected with either control siRNA or siRNA specific for STAT3 and treated with IL-6, and ChIP was carried out with either control IgG or anti-PU. Knockdown of STAT3 impaired PU.1 DNA binding to its consensus site in the CCL2 promoter ( Fig. 4D ). PU.1 binding to the Ϫ800/Ϫ1200 and Ϫ1/Ϫ400 regions in the STAT3 knockout cells was weaker than to the cells with nonspecific siRNA. No DNA binding was observed in the Ϫ400/Ϫ800 region in the STAT3 knockout cells.
To determine that CEBP␣, PU.1, and STAT3 form a transcriptional-regulatory complex, lysates from IL-6-treated hepatocytes were subjected to immunoprecipitation with either isotype control IgG, anti-CEBP␣, or anti-STAT3, followed by immunoblotting with anti-PU.1 or anti-STAT3. Both PU.1 and STAT3 were coimmunoprecipitated with endogenous CEBP␣, whereas no binding was observed with the control IgG (Fig. 4D, left) . PU.1 was coimmunoprecipitated with endogenous STAT3, and no binding was observed with the control IgG (Fig. 4D, right) .
To further define the interaction between CEBP␣, PU.1, and STAT3, HEPG2 cells were treated with IL-6 and coimmunostained with anti-STAT3/anti-CEBP␣, anti-PU.1/anti-STAT3, or anti-PU.1/anti-CEBP␣. All three transcription factors primarily colocalized to the nucleus (Fig. 4E ; for high-resolution images and controls, see Fig. S2 and S3 in the supplemental material). The nuclear colocalization of STAT3 with CEBP␣ (Fig. 4E, top) , PU.1 
miRNA-449a and miRNA-107 regulate IL-6-mediated CCL2 expression and STAT3 phosphorylation by targeting IL-6R and JAK1.
To define the role of STAT3 in IL-6-mediated CCL2 expression, IL-6R or JAK1 knockout hepatocytes were treated or not with the Ϫ2,000-bp CCL2 promoter-driven luciferase construct, in addition to a control vector or vectors expressing CEBP␣, PU.1, and STAT3 or any two of these factors. Luciferase activity was measured as described for Fig. 2A. (Bottom) Overexpression of CEBP␣, PU.1, or STAT3 was verified by immunoblotting with anti-CEBP␣, anti-PU.1, or anti-STAT3. (C) Hepatocytes were transfected with the CCL2 promoter-driven luciferase construct, in addition to either nonspecific (control) siRNA or siRNAs specific for CEBP␣, PU.1, STAT3, or any two of these factors. Luciferase activity was measured as described for Fig. 2A . *, P value obtained by a two-tailed t test between the control and the individual transcription factors; **, P value between cotransfected transcription factors and either factor alone. (D) Essential regions in the CCL2 promoter required for IL-6-mediated expression. Hepatocytes were transfected with luciferase reporters driven by deletion constructs of CCL2 promoter constructs (bp Ϫ2000, Ϫ8000, Ϫ300, or Ϫ300 with STAT3 binding site mutated [*]) (black bars) with (ϩ) or without (Ϫ) IL-6. Luciferase activity was measured as described for Fig. 2A . *, P value obtained by a two-tailed t test between conditions with or without IL-6. with IL-6 and subjected to immunoblotting using anti-pSTAT3, which is specific for the phosphorylated form of STAT3. IL-6 treatment resulted in increased accumulation of phosphorylated STAT3, and knockdown of IL-6R and JAK1 resulted in impairment of IL-6-mediated STAT3 phosphorylation (Fig. 5A) .
To test whether HCV-mediated upregulation of CCL2 is regulated by miRNAs, human hepatocytes were transfected with the CCL2 reporter construct, along with a control vector or vector expressing miRNA-449a and/or miRNA-107, and treated or not with IL-6. Expression of either miRNA-449a or miRNA-107 resulted in significant impairment (Ͼ2.5-fold) of IL-6-mediated expression of CCL2 (Fig. 5B ). Expression of both miRNA-449a and miRNA-107 resulted in further impairment (6.1-fold) of CCL2 activation compared to either miRNA alone, indicating cooperation between the two miRNAs ( Fig. 5B) . Expression of either of these miRNAs also resulted in decreased CCL2 protein and STAT3 phosphorylation (Fig. 5C ), which was further accentuated by expression of both miRNAs together, indicating cooperation in mediating transcriptional signaling (Fig. 5D ).
Computational target prediction of miRNA-449a and miRNA-107 using Targetscan identified the 3=-UTR regions of IL-6R and JAK1, respectively, as putative targets for translational silencing (Fig. 6A and E) . To test the specificity of these miRNAs, hepatocytes were transfected with a luciferase reporter containing the 3=-UTR region of IL-6R or JAK1, along with either control vector or vector expressing miRNA-449a or miRNA-107, and luciferase activity was measured. Expression of miRNA-449a and miRNA-107 resulted in significant reduction in the IL-6R (3.8-fold) and JAK1 (3-fold) UTR reporter activity, indicating direct interaction between the miRNAs and the 3=-UTR regions ( Fig. 6B and F) . To further demonstrate that these miRNAs impair gene expression, hepatocytes were transfected with either control vector or vector expressing miRNA-449a or miRNA-107, and expression of IL-6R and/or JAK1 was determined by qPCR and immunoblotting. Increased expression of miRNA-449a or miRNA-107 resulted in more than 2-fold downregulation of IL-6R (55%) and JAK1 (67%) RNA and protein levels (Fig. 6C, D, G, and H) .
IL-6R, JAK1, PU.1, and STAT3 are upregulated in HCV patients. To determine whether downregulation of miRNA-449a and miRNA-107 in HCV livers is accompanied by upregulation of their respective targets, IL-6R and JAK1, RNA was isolated from 10 normal, 10 alcoholic-hepatitis, 10 NASH, and 10 chronic-HCV livers. qPCR analysis showed that IL-6R and JAK1 are upregulated more than 2-fold (2.7-and 2.2-fold, respectively) in HCV livers ( Fig. 7A and B) . In contrast, no significant difference in the expression of IL-6R and JAK1 was noted in alcoholic-hepatitis, NASH, and normal livers. These results, along with our results from in vitro studies using human hepatocytes, clearly indicate that upregulation of IL-6R, JAK1, and CCL2 (Fig. 1C ) in HCV livers can be attributed to downregulation of miRNA-449a and miRNA-107.
Expression analysis of the transcription factors also showed that PU.1 is upregulated (3.6-fold) only in HCV livers compared to non-HCV and normal livers (Fig. 7C ). However, expression of STAT3 is upregulated 2.4-fold in alcoholic-hepatitis patients, 3.1fold in NASH patients, and 6.6-fold in HCV livers compared to normal livers (Fig. 7D ). We did not detect any differences in the expression of CEBP␣ in any of these patient populations (Fig. 7E) . GAPDH was used as the internal control.
DISCUSSION
HCV infection has been shown to induce inflammatory cytokines/ chemokines, leading to activation of hepatic stellate cells (HSCs) and development of fibrosis (26) . We have previously identified differential regulation of inflammatory cytokines, such as IL-17, IL-1␤, IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), gamma interferon (IFN-␥), IL-4, IL-5, IL-10, and YKL40 in HCV patients with fibrosis (23, 27) . In this study, we demonstrate that HCV-mediated specific regulation of miRNA-449a and miRNA-107 alters expression of CCL2, a major inflammatory chemokine that is regulated by the IL-6R complex components IL-6R and JAK1. It is known that CCL2 is expressed in the HSCs, regulates HSC chemotaxis to the site of injury, and promotes HCV-induced hepatic fibrosis (28) (29) (30) . Increased expression of CCL2 is associated with chronic HCV infection, and IFN-␣ therapy has been shown to reduce its expression (9) . Further, inhibition of CCL2 results in reduced cellular infiltration, steatohepatitis, inflammatory responses, and fibrosis during liver injury (31, 32) . IL-6 has also been shown to be upregulated in HCV patients through NS5A-mediated induction of Toll-like receptor 4 (TLR4) (33) , and IL-6 can induce CCL2, leading to increased inflammatory responses (34) . The results presented in this report indicate that HCV-induced induction of IL-6 can also lead to induction of CCL2, resulting in HSC chemotaxis and hepatic fibrosis (Fig. 2) .
Transcription factors play a significant role in regulating inflammatory responses, development of fibrosis, and HCC. Our results demonstrate that CEBP␣, PU.1, and STAT3 form a functional transcriptional-activation complex to regulate CCL2 ex- pression in hepatocytes ( Fig. 3 and 4 ). CEBP␣ has been shown to regulate HSC activation, which plays a major role in hepatic fibrosis (35, 36) . PU.1 knockout mice lack neutrophils, macrophages, and mast cells and do not elicit inflammatory responses or fibrosis (37) . Both CEBP␣ and PU.1 bind and cooperate to activate expression of myeloid-specific genes, such as murine neutrophil elastase promoter and granulocyte colony-stimulating factor (G-CSF) receptor, which is necessary for neutrophil differentiation (38, 39) . Further, STAT3 binding to the PU.1 promoter is required for its expression and subsequent hematological differentiation (40) . STAT3 has also been shown to bind to the promoter and activate CCL2 expression in rat smooth muscle cells (41) . Activated STAT3 is a proviral host factor and is required for HCV replication (42) . Therefore, the CEBP␣-PU.1-STAT3 transcription-regulatory complex plays a significant role in cellular differentiation, inflammatory gene expression, and development of hepatic fibrosis.
miRNAs are regulators of HCV infection, fibrosis, cirrhosis, and development of HCC following liver transplantation (21, 43) . miRNAs regulate cytokine signaling on HSCs and expression of inflammatory cytokines and interferons, leading to fibrosis (44, 45) . We have shown that miRNA-449a and miRNA-107 are specifically downregulated in HCV patients ( Fig. 1A and B ) and that miRNA-449a regulates expression of the inflammatory cytokine YKL40 through components of the NOTCH signaling pathway (23) . miRNA-125b and miRNA-124, which are downregulated in hepatocarcinoma patients, target IL-6R to modulate the IL-6/ STAT3 pathway and IL-6 production and induce tumorigenicity (46) (47) (48) . We demonstrate that expression of miRNA targets IL-6R and JAK1 and that transcription factors PU.1 and STAT3 are upregulated specifically in HCV patients compared to non-HCV patients and healthy individuals ( Fig. 7) . Although STAT3 was upregulated in alcoholic-hepatitis and NASH patients compared to healthy donors, the expression was 2-fold higher in HCV patients. We propose that in cases of HCV infection, the viral protein NS5A or the core protein may increase its expression and promote phosphorylation and nuclear translocation of STAT3 (49, 50) . Therefore, HCV-induced downregulation of miRNA-449a and miRNA-107 in human livers can activate transcriptional-regulatory complexes (CEBP␣-PU.1-STAT3) through modulation of cell surface receptor (IL-6R/JAK1) expression, thereby promoting inflammatory responses that lead to development of fibrosis and HCC (Fig. 8 ). Since we and others have found that CCL2 is also elevated in patients with alcoholic hepatitis and NASH (Fig. 1C ) (7) (8) (9) , although significantly lower than in HCV infection, it is possible that parallel gene-regulatory mechanisms may operate in non-HCV-mediated liver diseases.
Taken together, the results of this study provide novel insights into the miRNA-mediated gene regulation mechanisms that play a role in HCV-mediated inflammatory responses and development of liver fibrosis. The HCV-specific modulation of miRNA, transcription factors, and cell surface receptors identified in this report can be utilized for the potential development of noninvasive biomarkers that can identify HCV patients with higher risk for developing fibrosis, cirrhosis, and HCC, as well as in developing methods for altering miRNA expression levels (miRNA mimics or antagomirs) as a therapeutic strategy.
